Acalabrutinib monotherapy versus acalabrutinib plus obinutuzumab combination therapy in treatment-naïve chronic lymphocytic leukemia: A real-world' study of efficacy and safety at a tertiary academic medical center

Authors
Category Primary study
Conference67th American Society of Hematology Annual Meeting, ASH 2025
Year 2025
This article has no abstract
Epistemonikos ID: 64705e66a2e750ca337bb1c6ece2c9290efe260d
First added on: Jun 15, 2026